AstraZeneca to release a new pipeline of other medicines for the awaited coronavirus vaccine
On Thursday, AstraZeneca (AZN) announced progress in its pipeline of other medicines as it posted a mixed set of its third-quarter earnings results.
The British-Swedish drugmaker said that its third-quarter product sales reached $6.52 billion compared to its company-compiled consensus of $6.50 billion. The result excluded payments from collaborations.
However, the multinational pharmaceutical and biopharmaceutical company reported core earnings of 94 cents per share until the end of September 2020 which was lower than analysts’ expectations of 98 cents.
“We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic,” AstraZeneca’s Chief Executive Officer Pascal Soriot stated.
AstraZeneca’s total revenue growth slowed by 3% from 11%.